Pfizer plans to submit an sBLA by the end of this year, subject to discussions with U.S. FDA
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.
The FDA's Orphan Drug Designation is granted to investigational therapies addressing rare medical diseases or conditions that affect fewer than 200,000 people
The award was presented to her during a virtual ceremony on the occasion of 8th International Day of Yoga on 21st June 2022.
Acceptance based on results from the phase 3 KEYNOTE-091 trial
Dasatinib Tablet is indicated for the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive
Plans to establish six state of the art TaCa Centre for Surgery in next 2 years in these states
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
Subscribe To Our Newsletter & Stay Updated
